Last reviewed · How we verify
Rabeprazol
At a glance
| Generic name | Rabeprazol |
|---|---|
| Sponsor | Janssen-Cilag, S.A. |
| Target | Sterile alpha and TIR motif-containing protein 1, ATP-binding cassette sub-family G member 2, Adenosine receptor A3 |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | discontinued |
Approved indications
- Duodenal Ulcer due to H. Pylori
- Duodenal ulcer disease
- Gastroesophageal reflux disease
- Maintenance of Healing Gastroesophageal Reflux
- Multiple endocrine adenomas
- Pathological Gastric Hypersecretory Condition
- Peptic ulcer
- Systemic mast cell disease
- Zollinger-Ellison syndrome
Common side effects
Key clinical trials
- Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel. A Prospective, placebo-and Active Treatment-controlled, Open Label, Randomized 3-way Cross Over Study in Healthy Su (Phase 1)
- A Phase 1, Open-label, 4-period, Randomized 6-sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers (Phase 1)
- Relative Bioavailability of Tablet Formulation of Dabigatran Etexilate With and Without Co-administration of Rabeprazole in Healthy Male Subjects (an Open-label, Single-dose, Two-period, Single-arm St (Phase 1)
- Safety of Rabeprazole in Patients Under Multiple Treatments (N/A)
- Influence of Hygiene-dietetic Habits and Treatment Adherence on the Effectiveness of the Gastroesophageal Reflux Illness Treatment With Rabeprazol (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rabeprazol CI brief — competitive landscape report
- Rabeprazol updates RSS · CI watch RSS
- Janssen-Cilag, S.A. portfolio CI